Anonymous ID: 4fef8d May 9, 2018, 8:43 a.m. No.1348616   🗄️.is 🔗kun   >>8631 >>8635 >>9063

>>1348571

This is a problem the FDA could easily solve.

The limiting factor is approval of the autoinjector. A device.

 

The agency has had no problem fast tracking fucked up implantable devices because they are “substantially similar to and not different from” devices already on the market.

Hence the number of medical injury lawsuits.

 

But they won’t approve a “generic” epipen because the drug has “product exclusivity” due to the actual injector.

That way, Mylan can keep jacking up the price for a drug that costs literal pennies to make.

Anonymous ID: 4fef8d May 9, 2018, 8:46 a.m. No.1348648   🗄️.is 🔗kun   >>8667 >>8677 >>8934

>>1348604

There is no shortage of epinephrine. There will never be a shortage of epinephrine. It is one of the easiest drugs to manufacture.

The “shortage” is in the device, the autoinjector.

Simple proof of FDA, pharma collusion to bilk Americans out of money.

Anonymous ID: 4fef8d May 9, 2018, 8:49 a.m. No.1348676   🗄️.is 🔗kun   >>8934

>>1348635

Corruption at its finest.

The FDA is run by pharma, pure and simple.

 

Truth is…if they were fair, there is no money in epinephrine. A farmer with a lab kit could make it….

So they find other ways.

Anonymous ID: 4fef8d May 9, 2018, 8:55 a.m. No.1348718   🗄️.is 🔗kun   >>8934

>>1348678

It’s about 10x the cost of what it “used to be” even considering dollar value.

Price should have gone down, but they got new exclusivity to prevent generic entrants.

 

This is a version of what pharmabro shkrelli did.

They nailed him on something else to punish him for going around (((them))) to play their same game.

If (((they))) had done it, no one ever would have batted an eye.